0001209191-17-005608.txt : 20170125
0001209191-17-005608.hdr.sgml : 20170125
20170125191910
ACCESSION NUMBER: 0001209191-17-005608
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170125
FILED AS OF DATE: 20170125
DATE AS OF CHANGE: 20170125
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lydon Nicholas
CENTRAL INDEX KEY: 0001639935
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 17547682
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2017-01-25
0
0001370053
ANAPTYSBIO INC
ANAB
0001639935
Lydon Nicholas
C/O ANAPTYSBIO, INC.
10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
67332
D
Series B Preferred Stock
0.00
Common Stock
80877
D
Series C Preferred Stock
0.00
Common Stock
55403
D
Series D Preferred Stock
0.00
Common Stock
67345
D
Director Stock Option (right to buy)
1.12
2021-12-08
Common Stock
6828
D
Director Stock Option (right to buy)
0.70
2024-07-10
Common Stock
24184
D
Warrant to Purchase Series C Preferred Stock (right to buy)
4.55
2018-11-04
Series C Preferred Stock
16483
D
Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
The stock option is fully vested and immediately exercisable.
The stock option vested and became exercisable as to 25% of the shares subject to the option on January 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
This warrant is exercisable at any time.
/s/ Nicholas B. Lydon by Dominic Piscitelli, Attorney-in-Fact
2017-01-25
EX-24.3_696755
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints Hamza Suria, Dominic Piscitelli, Ryan McRobert, Nanette Agustines and
Winston Macaraeg, and each of them, as his or her true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as a representative of AnaptysBio, Inc. (the "Company"), any and all Form ID, or
Form 3, 4 or 5 reports and any amendments thereto required to be filed by the
undersigned in accordance with Section 16(a) of the Securities Exchange Act of
1934 (the "Exchange Act") and the rules thereunder with respect to transactions
in the Company's securities;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID, or Form
3, 4 or 5 report and any amendments thereto and timely file such report with the
U.S. Securities and Exchange Commission and any stock exchange or similar
authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney in-fact may approve in his or
her discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform each and every act and thing whatsoever
requisite, necessary, and proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or
cause to be done by virtue of this Power of Attorney and the rights and powers
herein granted. The undersigned acknowledges that no such attorney in-fact, in
serving in such capacity at the request of the undersigned, is hereby assuming,
nor is the Company hereby assuming, any of the undersigned's responsibilities to
comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Form 3, 4 or 5 reports with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 20th day of January, 2017.
/s/ Nicholas B. Lydon
Nicholas B. Lydon